

INTERNATIONALE GUIDELINE FÜR DIE BEHANDLUNG DER HUNTINGTON-KRANKHEIT

Frontiers in Neurology,

<https://doi.org/10.3389/fneur.2019.00710>

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



Disclaimer:

“The European Commission support for the production of this publication does not constitute endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.”

More information on the European Union is available on the Internet (<http://europa.eu>).

Luxembourg: Publications Office of the European Union, 2019

© European Union, 2019

Reproduction is authorised provided the source is acknowledged.

DAS EUROPÄISCHE REFERENZNETZWERK FÜR SELTENE NEUROLOGISCHE ERKRANKUNGEN (ERN-RND)

Das ERN-RND ist ein Europäisches Referenznetzwerk, das von der Europäischen Union eingerichtet wurde. ERN-RND ist ein Verbund der Krankenhäuser in der EU, die für die Versorgung von Menschen mit seltenen neurologischen Erkrankungen eine besondere Expertise besitzen. Ziel ist es eine verbesserte Versorgung von Patienten mit seltenen neurologischen Erkrankungen (rare neurological diseases - RND) zu erreichen. Die drei Säulen des ERN-RND sind: (I) Netzwerk bestehend aus Experten und Spezialzentren, (II) Entwicklung, Zusammenführung und Verbreitung von versorgungsrelevantem Wissen über seltene neurologische Erkrankungen, und (III) die Einrichtung und Nutzung von e-health Strukturen, die es ermöglichen, fallbezogenes Expertenwissen auszutauschen, ohne dass Patienten und Angehörige reisen müssen.

ERN-RND umfasst gegenwärtig 32 europäische Spezialzentren in 13 Mitgliedsstaaten, sowie mehrere, sehr aktive Patientenorganisationen. Die Spezialzentren befinden sich in Belgien, Bulgarien, Tschechien, Frankreich, Deutschland, Ungarn, Italien, Litauen, Niederlande, Polen, Slowenien, Spanien und Großbritannien.

ERN-RND deckt die folgenden Erkrankungsgruppen ab:

- Ataxien und hereditäre spastische Spinalparalysen (HSP)
- Atypische Parkinsonsyndrome und genetische Parkinsonerkrankungen
- Dystonien, Paroxysmale Erkrankungen und Neurodegeneration mit Eisenablagerungen im Gehirn (NBIA)
- Frontotemporale Demenz
- Huntington Erkrankung und andere Chorea
- Leukodystrophien

Mehr Informationen zum Netzwerk, den Spezialzentren und den oben genannten Erkrankungsgruppen finden Sie unter www.ern-rnd.eu

Bestätigung des Werts:

ERN-RND bestätigt den Wert dieser Guideline als gute klinische Praxis für die Behandlung der Huntington-Krankheit.

HAFTUNGSAUSCHLUSS

Bei den klinischen Leitlinien, Praxisempfehlungen, systematischen Übersichtsarbeiten und anderen Leitlinien, die von ERN-RND veröffentlicht, befürwortet oder in ihrem Wert bestätigt werden, handelt es sich um die Bewertung aktueller wissenschaftlicher und klinischer Informationen, die als Bildungsangebot zur Verfügung gestellt werden.

Die Informationen (1) umfassen möglicherweise nicht alle geeigneten Behandlungen und Pflegemethoden und sollen nicht als Feststellung des Pflegestandards betrachtet werden; (2) werden nicht laufend aktualisiert und spiegeln möglicherweise nicht die neuesten Erkenntnisse wider (zwischen der Erstellung dieser Informationen und ihrer Veröffentlichung bzw. Lektüre können sich neue Informationen ergeben haben); (3) beziehen sich nur auf die spezifisch angegebenen Fragestellungen; (4) schreiben keine bestimmte medizinische Versorgung vor; (5) ersetzen nicht das unabhängige professionelle Urteil des behandelnden Arztes, da die Informationen keine individuellen Unterschiede zwischen den Patienten berücksichtigen. In jedem Fall sollte die gewählte Vorgehensweise vom behandelnden Arzt individuell auf den jeweiligen Patienten abgestimmt werden. Die Nutzung der Informationen ist freiwillig. Die Informationen werden vom ERN-RND auf der Basis des Ist-Zustands zur Verfügung gestellt und ERN-RND übernimmt keine ausdrückliche oder stillschweigende Gewähr in Bezug auf die Informationen. ERN-RND lehnt ausdrücklich jegliche Gewähr der Gebrauchstauglichkeit und der Eignung für eine bestimmte Verwendung oder einen bestimmten Zweck ab. ERN-RND übernimmt keine Verantwortung für Personen- oder Sachschäden, die sich aus der Verwendung dieser Informationen ergeben oder damit im Zusammenhang stehen, noch für irgendwelche Fehler oder Unterlassungen.

LINK ZUR ORIGINALPUBLIKATION

<https://www.frontiersin.org/articles/10.3389/fneur.2019.00710/full>

GUIDELINE



International Guidelines for the Treatment of Huntington's Disease

Anne-Catherine Bachoud-Lévi^{1*}, Joaquim Ferreira², Renaud Massart¹, Katia Youssov¹, Anne Rosser³, Monica Busse⁴, David Craufurd^{5,6}, Ralf Reilmann^{7,8}, Giuseppe De Michele⁹, Daniela Rae¹⁰, Ferdinando Squitieri¹¹, Klaus Seppi¹², Charles Perrine¹³, Clarisse Scherer-Gagou¹⁴, Olivier Audrey¹⁴, Christophe Verny¹⁵ and Jean-Marc Burgunder¹⁶

¹ National Centre of Reference for Huntington's Disease, Henri Mondor Hospital, AP-HP, Créteil & NeurATRIS, Créteil, France, ² Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal, ³ IPMCN, School of Medicine, Cardiff University, Cardiff, United Kingdom, ⁴ Centre for Trials Research, Cardiff University, Cardiff, United Kingdom, ⁵ Division of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, Manchester Centre for Genomic Medicine, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, ⁶ Manchester Academic Health Science Centre, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁷ Department of Radiology, George-Huntington-Institute, Universitätsklinikum Muenster, Münster, Germany, ⁸ Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany, ⁹ Department of Neurosciences, Federico II University, Naples, Italy, ¹⁰ Department of Clinical Genetics, NHS Grampian, Aberdeen, United Kingdom, ¹¹ Huntington and Rare Diseases Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy, ¹² Department of Neurology, Medical University Innsbruck, Innsbruck, Austria, ¹³ Genetic Department, National Center of reference for Huntington's Disease, Salpêtrière Hospital, Paris, France, ¹⁴ Neurology Department, Angers University Hospital, Angers, France, ¹⁵ Neurology Department and UMR CNRS 6214 INSERM U1083, National Centre of Reference for Neurodegenerative Diseases, Angers University Hospital, Angers, France, ¹⁶ NeuroZentrumSiloah and Department of Neurology, Swiss HD Center, University of Bern, Bern, Switzerland

OPEN ACCESS

Edited by:

Pedro J. García-Ruiz,
University Hospital Fundación Jiménez
Díaz, Spain

Reviewed by:

Emilia Mabel Gatto,
Sanatorio de la Trinidad Mitre,
Argentina
Juan Carlos Martínez Castrillo,
Hospital Universitario Ramón y Cajal,
Spain

*Correspondence:

Anne-Catherine Bachoud-Lévi
bachoud@gmail.com

Specialty section:

This article was submitted to
Movement Disorders,
a section of the journal
Frontiers in Neurology

Received: 02 May 2019

Accepted: 17 June 2019

Published: 03 July 2019

Citation:

Bachoud-Lévi A-C, Ferreira J,
Massart R, Youssov K, Rosser A,
Busse M, Craufurd D, Reilmann R, De
Michele G, Rae D, Squitieri F, Seppi K,
Perrine C, Scherer-Gagou C,
Audrey O, Verny C and
Burgunder J-M (2019) International
Guidelines for the Treatment of
Huntington's Disease.
Front. Neurol. 10:710.
doi: 10.3389/fneur.2019.00710

The European Huntington's Disease Network (EHDN) commissioned an international task force to provide global evidence-based recommendations for everyday clinical practice for treatment of Huntington's disease (HD). The objectives of such guidelines are to standardize pharmacological, surgical and non-pharmacological treatment regimen and improve care and quality of life of patients. A formalized consensus method, adapted from the French Health Authority recommendations was used. First, national committees (French and English Experts) reviewed all studies published between 1965 and 2015 included dealing with HD symptoms classified in motor, cognitive, psychiatric, and somatic categories. Quality grades were attributed to these studies based on levels of scientific evidence. Provisional recommendations were formulated based on the strength and the accumulation of scientific evidence available. When evidence was not available, recommendations were framed based on professional agreement. A European Steering committee supervised the writing of the final recommendations through a consensus process involving two rounds of online questionnaire completion with international multidisciplinary HD health professionals. Patients' associations were invited to review the guidelines including the HD symptoms. Two hundred and nineteen statements were retained in the final guidelines. We suggest to use this adapted method associating evidence base–medicine and expert consensus to other rare diseases.

Keywords: Huntington's disease, guidelines, treatment, care, clinical practice

INTRODUCTION

HD is a rare neurodegenerative disorder of the central nervous system, with a genetic autosomal-dominant inheritance, that first involves basal ganglia (caudate nucleus and putamen) and results from expansion of a CAG trinucleotide repeat in the HTT (huntingtin) gene: alleles with 40 or more repeats are fully penetrant. The disease is characterized by motor, cognitive and psychiatric disorders, and a range of somatic symptoms. Progressive worsening leads to a bedridden state with cognitive deterioration. Death occurs about 20 years after the onset of symptoms.

More than a century after the first description of Huntington's disease (HD), there is still no curative treatment of the disease; however, symptomatic treatments are thought to be efficacious in controlling some of its troublesome symptoms. Yet, symptomatic management of HD remains inadequately documented (1–4), which may lead to variations in care mainly based on clinical experience and not on scientific evidence (5–7).

This document provides scientifically supported and consensual pharmacological, surgical and non-pharmacological recommendations for the treatment of HD.

MATERIALS AND METHODS

Methodology

The EHDN guidelines task force developed guidelines between 2015 and 2018 based on a formalized consensus method, adapted from the 2015 French Health Authority recommendations (HAS) (https://www.has-sante.fr/portail/jcms/c_272505/recommandations-par-consensus-formalize-rcf). This method combines exhaustive review of the literature, experts' proposals, and external scoring of the proposals until agreement (**Figure 1**). This is particularly suitable when at least two of the following conditions are met (1) absence or insufficiency of high-level evidence specifically addressing the questions asked; (2) possibility of declining the theme in easily identifiable clinical situations; (3) controversy, with the need to identify by an independent group situation in which a practice is deemed appropriate. Its main advantages are (1) its ability to identify the degree of agreement or indecision among experts (2) the strict independence between the steering group, which formulates the proposals to be put to the vote, and the rating group which judges the appropriateness.

Search Strategy

First, we conducted a search of scientific evidence published between 01/01/1965 and 01/08/2015 in the following databases: Cochrane Library, Embase, MEDLINE, PASCAL, BMJ Clinical Evidence, Current Contents, Infobanque AMC, National Guidelines Clearinghouse, PEDro, and BDSP (Public Health Database) as well as in the following websites: CEBAM, EBM sources, OMS Réseau de bases factuelles en santé, CBEM Oxford, Center for Evidence based child health, Center for health evidence, Center for reviews and Dissemination, Evidence based neurology, National institute for health and clinical excellence, Orphanet, ClinicalTrials.gov, OpenSIGLE

(System for Information on Gray Literature in Europe). We also hand searched abstracts of international congresses of the Movement Disorders Society. Search terms were chosen based on a list of symptoms to focus on determined following discussions within the guidelines committee and working groups (neuroprotective, rehabilitation, and cognitive) of the European Huntington's Disease Network. Search terms were: "Huntington disease," "drug therapy," and symptoms (Huntington chorea, drug therapy, Chorea, Dystonia, Falls, Chokes, Bradykinesia, Rigidity, Depression, Apathy, Irritability, aggression, Obsessions, perseverations, Anxiety, Agitation, Hallucinations, delusions, paranoia, Impatience, Impulsivity, Suicidal Ideation, Memory, Loss of fluency, speech, Dysarthria, Attention disorders, Social cognition impairments, Disorientation, Bradyphrenia, Indecision, Weight loss, Incontinence, Sleep disorders, Diarrhea, Sweating, Constipation, Vomiting, Swallowing, Pain, Dental decay, and Surgery).


Drug manufacturers and authors were also contacted in order to obtain additional information on unpublished trials. In total 637 publications were collected.

Data Extraction and Analysis

The Task Force committees reviewed the 637 collected publications with the French and UK committees focusing on pharmacological/surgical and non-pharmacological interventions, respectively. First, two members of each national committee conducted independently a screening of the collected publications and retained results from clinical trials, observational studies, meta-analysis, systematic reviews, case studies, previous recommendations, or conference and congress summaries. Studies including patients with HD clinical features and a confirmatory genetic diagnosis or a compatible family history (mostly for studies published before gene discovery in 1993) were also included 288 and 88 papers on pharmacological/surgical and non-pharmacological interventions, respectively, were retained for further analysis. The remaining members of the Task force validated the list of excluded publications. Second, a pair of members from each national committee summarized the key elements of the retained studies by filling a table with the following columns: authors, date of publication, type of intervention, daily dose (both of the active drug and the placebo), genetic characteristics of the patients (genetically diagnosed), study design, number of participants, duration of the study, primary and secondary endpoints, outcome, scales used, conclusion of the reviewers, and level of proof. Then they analyzed independently each study by assessing the methods (quality of the study) and results (the contents of the study) and assigned a level of scientific evidence according to the HAS classification (see below).

Quality Appraisal and Data Synthesis

Following the HAS recommendations, a quality grade was attributed to each study according to the level of scientific proof they provided (**Table 1**) (**Appendix 1**).

**TABLE 1** | Level of scientific evidence and gradation of studies.

Level of scientific proof provided by the study	Quality grade
Level 1	A
<ul style="list-style-type: none"> • Meta-analyses of randomized controlled trials • Randomized controlled trials of high power 	Established scientific proof
Level 2	B
<ul style="list-style-type: none"> • Randomized controlled trials of low power • Properly conducted non-randomized controlled trials • Cohort studies 	Scientific presumption
Level 3	C
Case-control studies	Low-level of scientific proof
Level 4	
<ul style="list-style-type: none"> • Comparative studies with major bias • Case series 	

Method for Reaching a Consensus

The subsequent steps for developing the guidelines are displayed in **Figure 1**. First, the experts of the national committees formulated provisional recommendations for each HD symptom, classified in four categories of disorders (motor, psychiatric, cognitive, and “others”). Recommendations were based on the synthesis of information from the studies, i.e., quality grade, accumulation of scientific evidence, and professional expertise. Recommendations were rated according to the quality grades of the studies on which they are based, with the highest quality grade determining the score. When scientific evidence was lacking, best clinical practice (professional agreement) was formulated, based on the experience of the National committees. The International Steering Committee reviewed the initial recommendations before initiating process to reach a consensus with the International Multidisciplinary HD Health Professionals group (**Table 2**). This involved two rounds of online questionnaire completion. After the first round, only appropriate recommendations with strong consensus were retained (**Table 3**). Those without strong consensus were reviewed and modified

by the International Steering Committee prior to the second round of ranking (**Table 3**). After the second round, all recommendations were deemed appropriate, and agreed as such, except two of the motor chapter and two of the psychiatric chapter. Two hundred and nineteen statements were retained in the final guidelines. The steering committee added a rider considered important by the multidisciplinary group to the four recommendations that did not reach a consensus. Whereas, the literature basis scored through survey monkey ends in 2015, experts' and knowledge input were provided through the survey scoring and comments as well as the last face-to-face meeting until October 2018.

Patients' Associations Involvement

European, Chinese and French HD associations as well as the Italian League for Research on Huntington and related diseases Foundation were invited to review the guidelines.

RESULTS

A condensed version of HD symptoms and recommendations is provided in the main text. A full version is available in **Appendix 2**. Publications justifying the grades of the recommendations are cited in the text. Recommendations provided without specific grading are underpinned by professional agreements.

Given that any HD symptoms may be worsened by stress, fatigue, and intercurrent disorders (e.g., anxiety, digestive disorders, infectious or painful conditions, etc.), these aspects must be assessed and should be treated with appropriate measures alongside managing the Huntington's symptoms.

Motor Disorders

The wide spectrum of motor manifestations are the best known and the most visible symptoms in HD. Among them, involuntary movements (i.e., chorea) are the most obvious. However, while the diagnosis of manifest HD is based on the presence of motor symptoms, these are frequently preceded by cognitive

TABLE 2 | Composition of the international multidisciplinary HD health professionals.

	Motor disorders		Cognitive disorders		Psychiatric disorders		Other disorders	
	1st survey	2nd survey	1st survey	2nd survey	1st survey	2nd survey	1st survey	2nd survey
Number of participants	67	38	63	36	60	32	56	30
Expertises								
Dentists	1	1	0	0	0	0	0	0
Geneticists	4	3	3	2	2	0	3	1
Neurologists	39	24	35	20	34	20	33	22
(Neuro)psychologists	8	2	11	6	10	4	7	2
Nurses	3	3	2	2	2	2	3	2
Physiotherapists	5	1	4	2	4	1	3	1
Psychiatrists	7	4	8	4	8	5	7	2
Countries								
Australia	Australia	Australia	Australia	Australia	Australia	Australia	Australia	Australia
Belgium	Brazil	Belgium	Belgium	Belgium	Belgium	Brazil	Belgium	Brazil
Brazil	Chile	Brazil	Brazil	Brazil	Brazil	Chile	Brazil	Chile
Chile	Cyprus	Chile	Chile	Chile	Chile	Cyprus	Chile	Czech R.
Cyprus	Czech R.	Cyprus	Cyprus	Cyprus	Cyprus	Czech R.	Cyprus	Denmark
Czech R.	Denmark	Czech R.	Czech R.	Czech R.	Czech R.	Denmark	Czech R.	Estonia
Denmark	Estonia	Denmark	Denmark	Denmark	Denmark	Estonia	Denmark	France
Estonia	France	Estonia	Estonia	Estonia	Estonia	France	Estonia	Italy
France	Germany	France	France	France	France	Italy	France	Netherlands
Germany	Hungary	Germany	Germany	Germany	Germany	Netherlands	Germany	Peru
Hungary	Italy	Italy	Italy	Italy	Italy	Peru	Italy	Poland
Italy	Netherlands	Netherlands	Netherlands	Netherlands	Netherlands	Poland	N. Zealand	Portugal
Netherlands	Poland	Poland	Poland	Poland	Peru	Portugal	Netherlands	Romania
Peru	Portugal	Portugal	Portugal	Portugal	Poland	Romania	Peru	Russia
Poland	Russia	Romania	Romania	Romania	Portugal	Russia	Poland	Switzerland
Portugal	Spain	Russia	Russia	Romania	Romania	Spain	Portugal	UK
Romania	Switzerland	Spain	Spain	Russia	Switzerland	Switzerland	Romania	USA
Russia	UK	Switzerland	Switzerland	Spain	UK	UK	Russia	
South Korea	USA	UK	UK	Switzerland	USA	USA	Spain	
Spain		USA	USA	UK			Switzerland	
Sweden				USA			UK	
Switzerland							USA	
UK								
USA								

and behavioral symptoms (8). While motor symptoms are easily detected, and might be the source of anxiety and ostracism, they are often well-tolerated by the patients and their proxies in contrast to cognitive and behavioral symptoms that often lead to family and social/professional's issues.

Chorea

Chorea is characterized by abnormal, involuntary, spontaneous, uncontrollable, irregular, intermittent, non-rhythmic and aimless movements affecting the trunk, the face, and the limbs.

Drug treatment should be considered if chorea causes the patient distress or discomfort.

Tetrabenazine is one of the first-line treatments for this symptom (Grade A) (9) unless the patient suffers from not well-managed depression or suicidal thoughts. Second generation neuroleptics (Grade B) (10, 11) are first-line treatments for this symptom in particular when the patients have associated personality and/or behavioral or psychotic disorders. Monotherapy to treat chorea is preferred because combination therapy increases the risk of adverse effects and may complicate the management of non-motor symptoms. In the presence of disturbing chorea, appropriate protective measures (especially during meal times and during the performance of

instrumental activities of daily living) should be put in place to avoid traumatic injury or chokes. Rehabilitation specialists can help identify appropriate assistive technology devices and positioning techniques.

Dystonia

Dystonia is characterized by abnormal postures that may affect all body segments and is frequently associated with rigidity (12). Dystonia intensity varies from a slight intermittent abnormal posture to severe twitch of muscles with major impact on movements and functions of daily living.

Both active and passive physiotherapy approaches are recommended as a preventive measure to maintain the range of joint motion, limit postural and musculoskeletal deformities and, prevent the development of contractures. Injection of botulinum toxin in the case of focal dystonia or to prevent secondary deformities should be performed by a trained professional. Customized chairs can provide a comfortable environment in view of the dystonia-related deformities.

Rigidity

Rigidity is an increase in muscle tone leading to a resistance to passive movement that can induce joint stiffness and

TABLE 3 | Rules to determine the strength of the consensus of the multidisciplinary experts.

Recommendations deemed as		1st round			2nd round	
		Median value	Responses' distribution	Submitted to the 2nd round	Median value	Responses' distribution
Appropriate	Strong agreement	≥ 7	All between (7-9)	No	≥ 7	All between (7-9); two values missing or < 7 tolerated
	Relative agreement	≥ 7	All between (5-9)	Yes	≥ 7	All between (5-9); two values missing and/or < 5 tolerated
Inappropriate	Strong disagreement	≤ 3	All between (1-3)	No	≤ 3	All between (1-3); two values missing or > 3 tolerated
	Relative disagreement	≤ 3.5	All between (1-5)	Yes	≤ 3.5	All between (1-5); two values missing or > 5 tolerated
Indeterminate	Indecision	Between [4-6.5]	Whatever the distribution	Yes	Between [4-6.5]	Whatever the distribution
	No consensus	≥ 7	At least one < 5 or missing	Yes	≥ 7	At least three < 5 or missing
		≤ 3.5	At least one > 5 or missing	Yes	≤ 3.5	At least three > 5 or missing

limited range of motion, which might be distressing for patients.

Rigidity may be increased or induced by the use of neuroleptics or tetrabenazine. If this impacts the functional capacity of the patient, a reduction in dosage or the withdrawal of neuroleptics and/or tetrabenazine should be considered considering overall benefit on chorea and/or behavioral symptoms vs. severity of rigidity.

Levodopa may provide partial and temporary relief of the akinetic-rigid symptoms of HD, especially in juvenile forms (Grade C) (13–18). Treatment with levodopa should be started gradually and the total daily dose is usually lower than in Parkinson's disease.

Physiotherapy is recommended to improve or maintain mobility and prevent the development of contractures and joint deformity (Grade C) (19).

Akathisia

Akathisia is a syndrome characterized by unpleasant sensations of "inner" restlessness that manifests as an inability to sit still.

An iatrogenic cause of akathisia should be investigated as the priority.

Tetrabenazine (Grade C) (20, 21), neuroleptics and Selective serotonin reuptake inhibitors (SSRI) may cause akathisia in HD and reducing the dose or changing the treatment may be helpful.

Swallowing Disorders

Swallowing disorders can occur in patients at the early stages of the disease and become a major problem in later stages by inducing repeated choking and leading to secondary bronchopulmonary infections or even cardiac arrest.

Regular assessment of swallowing disorders should be provided throughout the progression of the disease (Grade C) (22) and referral to a Speech and Language Therapist is recommended as soon as the disorders appear (Grade C) (22–24).

Ancillary assessments that may help in managing swallowing disorders include: generalized motor skills, respiratory status, dental health, mood, behavior and emotional status, cognition, nutrition, and hydration status. Provision of information and advice on safe swallowing procedures, on posture and positional changes can help to avoid aspirations and leads to improvement of swallowing disorders. Oral-facial exercise with swallow sequence individualization and cough post swallow may also improve swallowing difficulties. In some cases, treating chorea might help in improving swallowing problems. However, side effects of treatments for chorea (e.g., sedation, attention, and parkinsonism) might also negatively impact swallowing capacities.

The education of carers is important as they are often managing the eating, drinking, and swallowing regime.

For severe swallowing disorders impacting nutrition and quality of life of the patient, the use of a gastrostomy device Percutaneous Endoscopic Gastrostomy (PEG) may be considered and should be discussed on a case-by-case basis with the patient and the caregivers. PEG should be anticipated and discussed with relatives and patients still able to understand the benefits and burdens of the methods. Before advanced stages of the disease, patients should be educated to make an informed choice concerning the PEG methods even if they can change their decision at any time.

Myoclonus

Myoclonus refers to sudden muscle contractions, brief and involuntary, axial, in extremities or generalized, similar to spasms and jerks in epileptic seizures but not related epilepsy. In HD, myoclonus can be observed in a predominant akineto-rigid phenotype and can be associated with an at rest or action tremor, especially in the juvenile forms but also in later-onset forms. In juvenile forms, non-epileptic myoclonus can coexist with epilepsy.

In case of myoclonus impacting the functional capacity of the patients, treatment with sodium valproate or clonazepam, used alone or in combination, and in escalating doses, is recommended (Grade C) (25–32). Levetiracetam is a therapeutic alternative for the same indication. In case of myoclonus of cortical origin that is not associated with epileptic seizures, piracetam has a marketing authorization (Grade C) (29). Benzodiazepines, in particular clonazepam, may be used to manage myoclonus whilst remaining vigilant with regard to adverse effects such as somnolence and increasing falls, and the risk of drug-dependence.

Gait and Balance Disorders

Gait and balance disorders impairments include disruption of cadence regulation, increased variability of step width and length, disturbed initiation and increased postural sway (33). These develop as a result of the progressive complex movement disorder seen in HD adding to the overall burden of motor morbidity with falls and loss of independence in HD (34).

Generally, interventions for gait and balance should start as early as possible and be continued and adapted throughout the progression of the disease (Grade C) (33, 35–38). Physiotherapy interventions (Grade B) (39–42) and the introduction of falls prevention programs, gait, core stability, and balance interventions (Grade C) (35, 43–45) as well as attentional training are recommended.

Pharmaceutical management of chorea may improve walking and balance as they can be affected by chorea (Grade C) (46–49). However, they should always be used cautiously and regularly reassessed as their adverse effects may also aggravate walking disorders.

Maintaining physical activity and low impact exercises is recommended.

The use of assistive devices such as four-wheeled walker (Grade B) (50) as recommended by Physiotherapist or Occupational Therapist should be considered to improve stability and reduce fall risk.

Bruxism

Bruxism is an involuntary clenching with excessive contraction of the jaw muscles. It typically causes lateral movements (or front to back) responsible for gnashing and can lead to tooth damage.

Injecting botulin toxin A into the masseter muscles is proposed as the first-line treatment of bruxism (Grade C) (51). Customized protective mouth guards may be used to reduce the complications of bruxism on a case-by-case basis, mostly in early stage patients.

Bruxism may occur as a side effect of neuroleptics (Grade C) (51, 52) and serotonin reuptake inhibitors, thus reducing their dose should be considered.

Manual Dexterity

Manual dexterity can be impaired secondary to chorea/dystonia/akinesia/rigidity but also occur in their absence—due to abnormal motor planning and sequencing.

Neuroleptics and tetrabenazine may possibly have a beneficial effect on dexterity as a result of reducing chorea (Grade C)

(46, 47, 53) but may also have a detrimental effect on dexterity by aggravating other symptoms such as bradykinesia.

Management with physiotherapy and occupational therapy may be useful to reduce the functional impact of fine motor skill deterioration (Grade B) (41). Adaptive aids may help to compensate for the deterioration of manual dexterity.

Global Motor Capacities

Early referral to a physiotherapist is recommended in order to facilitate the development of a therapeutic relationship, promote sustainable exercise behaviors and ensure long-term functional independence.

Physiotherapy and/or personalized exercise programs (Grade B) (40) are beneficial for the overall functional ability, motor function, and independence in HD, in combination with pharmacological treatments (Grade B) (39, 40, 42).

Cognitive Disorders

Cognitive deficits appear frequently before motor symptoms (8). They are, in addition to behavioral symptoms, the major cause of family disruption and social withdrawal (54). Cognitive symptoms cause intense psychological discomfort and a sense of powerlessness that can lead to behavioral symptoms.

Based on present knowledge, no pharmacological treatment is recommended for the treatment of cognitive symptoms.

Multiple rehabilitation strategies (speech therapy, occupational therapy, cognitive and psychomotricity) might improve or stabilize transiently cognitive functions at some point of time in the course of the disease (Grade B) (55).

Executive Functions

Executive functions refer to the functions that allow the realization of complex task in daily living. They consist in a set of functions mostly dedicated to cognitive and behavior control and adaptation, which may be impaired in HD, even at the premanifest stages and thus impose adaptation from the environment, organization support including proactivity in planning appointments, behavior or daily life activities like cooking.

For the patients to maintain their independence for as long as possible, it is better to help the patients organize themselves and initiate activities rather than substitute for them, as long as they do not endanger themselves.

Treatment for anxiety and depression may help to improve executive function and cognitive stimulation through rehabilitation may improve planning and initiation more specifically (Grade C) (56). Sedative drugs and neuroleptics should be closely monitored as they impair executive functions and attention.

Bradyphrenia

Bradyphrenia is defined by slowing of cognitive information processing and a prolongation of reaction time depending on the complexity of the cognitive task (57). It becomes more apparent with HD disease progression.

Management is based on giving the patient enough time to process information and perform a task and avoiding time-pressured situations. Cognitive stimulation as part of rehabilitation may be beneficial.

Language and Communication Disorders

Language and communication disorders can be divided in speech and language disorders *per se*. Speech disorders consist of slurred and slowed speech causing dysarthria, inappropriate pauses or bursts of speech, and progressive reduction in verbal fluency (58). Language (e.g., syntax) impairments appears early in the disease course, with progressive difficulties in understanding and producing complex sentences. Reduction of lexical capacities appears later. This often goes unnoticed and may cause misunderstanding and impaired communication.

The changing communication needs of the person with HD should be reassessed throughout the course of the disease to plan effective management strategies (Grade C) (59). As communication disorder in HD is variable, its monitoring requires comprehensive assessment of language and of other factors such as mood, motivation, and behavior.

Early referral to Speech and Language Therapists is recommended (Grade C) (59) as they can play a major role in assessing and managing communication problems in HD at all stages of the disease. Communication strategies and techniques may include: management options (e.g., voice therapy techniques), advice on facilitation of communication (e.g., allowing time for communication, reduction of environmental distractions and noise) and the use of simple techniques (e.g., gestures and rephrasing) or tools (e.g., pen and phones).

Family members and other communication partners should be educated to support patients to attempt verbal communication as long as possible. Augmentative and alternative communication (talking mats) can compensate for communication difficulties and increase the individual's chance of participation in daily life. These strategies need to be implemented whilst there is still motivation and a capacity to learn (Grade C) (60).

Social Cognition Impairments

Social cognition impairments refer to a set of symptoms that affect relationships and social behavior. The most studied are the inability to recognize emotion others (61) but also to express emotions, both through facial expression or through the voice. Executive function impairments can make difficult for the patients to express their feelings. The capacity to infer other thoughts or feeling, are also reported to be impaired in patients (61). Furthermore, motor impairments can create a "facial mask," often misunderstood as indifference.

Improvement of behavioral disorders may help with social and family integration. However, impact of SSRI or neuroleptics on social interaction *per se* has not yet been properly assessed to allow any recommendation specific to this domain.

Explaining the patients' disorders to their family, health care professionals or to their colleagues may facilitate the patient's social relationships. Moreover, third party intervention (e.g., caregiver, nurse, and social worker) may stimulate patients' social interaction.

Memory Disorders

Memory disorders are frequently reported in HD and may be confounded with or exacerbated by attention disorders. They are

mostly characterized by difficulties in learning new information and retrieving information acquired (62).

Strategies such as establishing and keeping a regular daily routine may compensate memory loss. Rehabilitative approaches (speech therapy or neuropsychology) may help memory as part of an overall intervention plan. Specifically, domain-specific transcoding (verbal and visual) may help in recalling items.

Sedative drugs, neuroleptics and tetrabenazine may impact negatively on memory.

Disorientation

Disorientation, both in time and space, appear during the progression of HD but temporal orientation is altered earlier (63–66).

Investigations should be carried out to detect any potential intercurrent cause for a confusional state. Establishing a regular routine, in tune with the patient's environment as much as possible, and milestones enables the patient to manage their time better.

Visuospatial and Visual Perceptual Disorders

Visuospatial and visual perceptual disorders appear late in the course of the disease through interference with the integration and understanding of visual information (66).

It may be useful to make the patient's environment safe (padding furniture) to minimize falls and shocks linked to visual spatial difficulties and aggravated by motor disorders.

Psychiatric Disorders

Behavioral symptoms may appear before the motor diagnosis of the disease. They are, in addition to and in conjunction with cognitive symptoms, the major cause of family disruption, social isolation, and withdrawal.

Their management should be based on the identification of the underlying triggers causing changes in mood or behavior. Patients should be given the opportunity to express their worries and frustrations.

Using methods to calm and reassure patients is a major component of care of psychiatric disorders. Based on data from other neurodegenerative conditions, mindfulness-based cognitive therapy and Acceptance and Commitment Therapy may be useful in HD.

Depression

Depression is one of the most common psychiatric symptoms seen in HD (67, 68) with a significant negative impact on quality of life. It may affect patients at any stage of the disease, even before motor manifestation (69). Thus, vigilance to detect and treat depression is required at all stages of the disease.

Psychotherapy and cognitive behavioral therapy may enable early detection of mood changes. An antidepressant may be suggested if depression occurs in HD (Grade B) (70). It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI), or alternatively Mianserin or Mirtazapine, in case of sleep disruption. In case of recurrent depression, long-term mood-stabilizer treatment may be introduced in complement to the treatment of the current episode to prevent relapses. If depression is thought to be an

adverse effect of other medication, the dosage of the responsible drug should be reduced gradually. In the case of resistant depression, or depression associated with psychotic symptoms, a psychiatrist should be consulted. In case of severe depression and resistant to oral medications, electroconvulsive therapy (ECT) may be suggested under the guidance of a psychiatrist (Grade C) (71–73).

Suicidal Ideation or Attempts

Suicidal ideation or attempts are common in HD (74) and correlate with family history of suicide, a history of previous suicide attempts and the presence of depression, especially in prodromal stages (75).

Suicide risk should be assessed in HD irrespective of the stage, being particularly vigilant at the time of diagnosis and when the disease starts to impact on day-to-day life. Prevention of suicide includes treating risk factors such as underlying depression, social isolation and impulsivity.

Irritability

Irritability is a very common symptom in HD (67, 68, 76). This disorder is of fluctuating nature, characterized by impatience and a tendency to become angry in response to minimal provocation. Overflow and loss of control are favored by impulsivity, and can lead to aggressive behavior toward self or others, and rarely, to criminal behavior. This symptom can be caused by the frustrations felt by the patient because of the great loss of his capacities, and by troubles in expressing himself, as well as by neurological/psychological fatigue brought by the latter.

Before initiating pharmacological treatment, possible environmental causes for the patient's frustration and irritability should be explored. In order to reduce irritability, behavioral strategies should be considered. A structured plan with a regular routine in a calming environment is desirable. In addition, psycho-education for the patient's family regarding diversion strategies should be attempted to avoid confrontation as much as possible.

Whilst SSRIs are first lines for irritability (Grade C) (77, 78), it may be necessary to use them at or near the maximum recommended dose in order to be effective. Irritable patients who do not benefit from an SSRI alone may benefit from combination therapy with Mianserine or Mirtazapine, especially when sleep disorders are present. In patients with aggressive behavior, the recommended first-line treatment is a neuroleptic (Grade C) (79–81). In case of overt aggression associated with depression, neuroleptic treatment should be associated with sedative antidepressants. If irritability does not respond to antidepressant therapies and/or neuroleptics, a mood stabilizer (Grade C) (82, 83) can be added.

Apathy

Apathy has been defined by Levy and Czernecki (84) as “a quantifiable reduction in goal-directed behavior,” manifesting clinically as a reduction in interest, spontaneity, motivation, and drive. In patients with HD it is compounded by emotional blunting, resulting in social withdrawal, and lack of concern for others. It is the most frequent psychological and behavioral

symptom in HD, especially in the middle and later stages, causing a severe reduction in the activities of daily living and often being a source of conflict in the family. With regard to cognitive and psychological symptoms, apathy and irritability are the two faces of the same coin (85). A patient can be apathic the morning and irritable the afternoon, depending on the situation. As for irritability, apathy can be caused by environmental and psychological issues. Apathy may also be an adaptive response when the patient feels overwhelmed by too much stimulation (HD patients are more sensitive to noise and environmental interferences), or with the feeling that his/her disease is progressing.

It is important to explain the various aspects and causes of the apathy to the family circle.

Personalized cognitive stimulation, establishing routines and a structured programme of activities is recommended when possible. A professional intervention at home can improve compliance and reduce the patient's opposition and irritability.

Depression may increase apathy. If depression is suspected, an SSRI should be tried.

Sedative medication may increase apathy, thus avoiding unnecessary prescription or reduce dosage is recommended.

Anxiety

Anxiety as defined by the uncomfortable feeling of nervousness or worry about something that is happening or might happen in the future, is common in HD. Anxiety is linked to the other symptoms (motor and cognitive), as the patient is anxious because of the loss of essential functions, and correlated to family, social and economic issues, and to the burden of his pathology (and the one of his proxies). However, anxiety does not increase with disease progression. It is associated with depression, suicide, irritability, quality of life, pain, illness beliefs, and coping.

SSRI or SNRI are first line treatments of anxiety, especially when associated with depression. On-demand prescription of an anxiolytic might be beneficial, but caution is required because of the associated risk of worsening or causing falls. Neuroleptics (Grade C) (86, 87) are valuable therapeutic alternatives in the treatment of anxiety when other treatments fail.

Obsessions

Obsessions are defined by recurrent and persistent thoughts, ideas or images that do not let the mind rest, causing anxiety. True obsessions, according to this definition, are not very common in patients with HD, but perseveration is very common, particularly in the middle and later stages (76). Perseveration may be defined as the repetition of a thought, behavior or emotion beyond the psychological context in which it arose, and in patients with HD these repetitive thoughts and behaviors can persist for hours, months, or even years after the original trigger. Patients have little or no insight into the problem (in contrast to obsessional thoughts, which are distressing and recognized as abnormal); however, it has been shown that perseveration is the one behavioral symptom in HD which has a significant negative impact on the quality of life of family members and caregivers (88).

Over the course of HD, symptoms may change and repetitive thoughts may replace obsessive–compulsive disorder. The distinction between obsessive–compulsive phenomena and perseverations is important for the care strategy, both requiring differential approaches.

If pharmacological treatment is necessary for perseverative symptoms, an SSRI could be prescribed (Grade C) (89), in particular when symptoms are associated with anxiety. Olanzapine and risperidone (Grade C) (81, 86) are two valuable therapeutics for ideational perseverations, in particular when they are associated with irritability.

True obsessive–compulsive phenomena are sensitive to psychological intervention, such as Cognitive Behavioral Therapy, in non-cognitively impaired patients. If pharmacological treatment is necessary for obsessive–compulsive phenomena, a SSRI should be prescribed as first-line treatment (Grade C) (89).

Impulsivity

Impulsivity consists of acting without prior planning, which can lead to unpredictable behavior. When impulsivity is associated with depression or irritability, there is a significant increased risk of self-harm or suicide or aggressiveness. Impulsivity may be the result of cognitive impairments, which lead to an intense frustration toward patience, the patient being in the incapacity to wait or to deal cognitively with planning. Impulsivity may then be an adaptive response to language difficulties of patients who cannot explain what stresses them.

When impulsivity is associated with depression or personality disorders, there is a risk of auto- or hetero-aggressiveness, which justifies the prescription of a neuroleptic in combination with a SSRI. Long-term mood-stabilizer treatment may be introduced in the case of mood lability and impulsivity.

Sexual Disorders

Sexual disorders are very common in HD. Decreased libido is the most common symptom while hypersexuality or disinhibited behavior are rarer, but can cause significant problems in relationships. Repetitive hypersexual behaviors are often a result of perseveration.

Identifying the existence of sexual disorders and determining their triggers and their impact on relationships is important. Psychological support and/or referral to a specialist in psychosexual disorders might be useful. In the case of decreased libido, an iatrogenic cause should be investigated (e.g., the use of an SSRI) and reducing the dose or substituting the treatment responsible may be suggested. In the case of erectile dysfunction, treatment for impotence may be suggested and seeking the opinion of an endocrinologist and/or a specialist in psycho-sexual disorders may be useful. In case of impotence, prescription of phosphodiesterase 5 inhibitors should be considered in the clinic when asked for by the patient and his sexual partner. A behavioral and psychological approach is useful in the case of hypersexuality, by re-establishing appropriate standards of behavior in the patient's social setting. If hypersexuality involves social discomfort or violence, the proposed first-line treatment is a neuroleptic (Grade C) (90) and/or a SSRI. If the treatment for

hypersexuality with neuroleptics and/or SSRI is not successful, the addition of or substitution for an anti-androgen may be proposed (Grade C) (91–93) under the guidance of a specialist in sexual disorders or an endocrinologist. Where hypersexuality poses a risk to others, specific measures should immediately be put in place (e.g., referral to a psychiatrist).

Hallucinations

Hallucinations are defined as a perception without an object, at which the subject adheres to and reacts as if the perception came from outside. Delusions are false beliefs based on incorrect inferences about external reality, the cultural and social context to which the patient belongs.

The use by the patient of psychotropic agents should be searched for and interrupted in case of hallucinations and delusions. Second generation neuroleptics are the first line treatment for hallucinations and delusions (Grade C) (80, 81, 86, 94–106). Clozapine should be proposed as the first-line treatment in the case of akinetic forms of HD with debilitating Parkinsonian symptoms. Perseverative ideation can sometimes mimic psychotic symptoms, and in such circumstances the patient may benefit from treatment with serotonergic antidepressants in combination with an atypical neuroleptic. Psychiatric intervention and support are particularly useful in the case of psychotic disorders occurring in HD, for treatment adjustments. If pharmacological treatments fail, the option of ECT can be discussed with psychiatrists (Grade C) (71, 73, 107).

In case of agitation, priority should be given to identifying environmental or somatic triggers (bladder distension, fecal impaction, pain, etc.) in order to treat the underlying cause, especially in the advanced stages of the disease when communication difficulties exist. When agitation is associated with an anxiety disorder, a benzodiazepine should be prescribed as needed to reduce the risk of dependence and falls (Professional agreement). Some benzodiazepines (e.g., midazolam) may be useful in emergency situations. Long-term treatment with benzodiazepines should be avoided as much as possible but remains necessary in some patients. In the case of extreme agitation, and if there are associated behavioral and personality disorders, it is advised to prescribe a neuroleptic (Grade C) (82, 90, 91, 102, 108, 109).

Other Disorders

Other symptoms than motor, cognitive and psychiatric disorders are often present. Among those, weight loss, dysphagia, and sleep disturbance are not unfrequently the most prominent symptoms. As they may cause discomfort, they should be looked for in order to limit them when present.

Sleep Disorders

Sleep disorders are common in HD. Around two-thirds of HD patients suffer from sleep disorders, with diverse causes such as depression, anxiety, intrinsic alteration in the circadian sleep-wake rhythm, and involuntary movements during sleep inducing awakenings (110, 111). They may present as difficulties in falling asleep and/or early awakenings in the middle of the

night followed by insomnia. They may be associated with aimless wandering, and lead to difficulties in coping by the proxies. However, disturbances of diurnal rhythm (day-night reversal, etc.) are probably more common than simple insomnia in HD patients.

Potential underlying cause of sleep-related difficulties (e.g., depressive syndrome, anxiety, and severe involuntary movements) should be investigated. Simple lifestyle and dietary strategies (e.g., avoiding long nap, having no stimulants after 4 pm) are the first-line treatment of insomnia. When lifestyle strategies are ineffective to treat insomnia, prescribing a hypnotic may be suggested for a short duration to avoid the risk of drug dependence. Some agents may be proposed in place of a hypnotic and for a long duration (e.g., mianserin, mirtazapine, and antihistaminic drugs) as they have a reduced tendency for causing dependency. Melatonin may be suggested in case of sleep phase inversion. A neuroleptic should be prescribed in the evening when sleep disorders are associated with behavioral disorders or chorea.

Urinary Incontinence

Urinary incontinence may either be multifunctional or linked to a deterioration of the frontal lobe control centers, causing an overactive bladder with urge incontinence and/or unannounced urination (112).

Where there is urinary incontinence, a precipitating factor should always be investigated (urinary infection, prostate disease). It is useful to investigate the presence of diurnal unexpected complete urination (complete and sudden bladder emptying, without urge) for which carbamazepine may be of benefit (Grade C) (112). In the case of an overactive bladder with leakage and urge incontinence, therapy with selective antimuscarinic may be tried, whilst watching out for the appearance of potential side effects, in particular confusional state. If, after few weeks, the incontinence therapy has not been effective, it should be stopped. If simple therapeutic measures have failed, it is advised to undergo urodynamic testing to help guide the choice of drug therapy and to consult a urologist if necessary.

In all cases, it is recommended to implement simple lifestyle strategies: urination before every outing and at regular times.

Pain

Pain assessment is sometimes difficult because of communication disorders. Moreover, because of communication's disorders and a tendency for these patients not to complain, pain is often related to non-verbal language and behavioral disorders such as irritability and restfulness.

Behavioral change or worsening of involuntary movements should trigger the search for an underlying source of discomfort, and in particular pain.

Dental Pain

Patients suffer from poor oral health for a variety of reasons, including impaired motor ability (e.g., difficulties brushing teeth) or reduced motivation to maintain oral health, the use of drugs

affecting salivary secretion and frequent dental trauma due to falls and injuries, bruxism.

Multidisciplinary teamwork, especially with dietitians to avoid highly cariogenic foods, is recommended (Grade C) (113, 114). Verbal and written instructions on how to provide good oral hygiene at home should be given to patients and carers (Grade C) (114, 115). Dental care including descaling by a dentist or dental hygienist should be carried out at least once a year but should be more frequent in the later stages of the disease.

At later stages of the disease, treatment options should be discussed carefully and in advance. Treatment intervention, especially in late stage disease may require conscious sedation (midazolam, Diazepam) or general anesthesia in a hospital setting (Grade C) (115–117).

In view of the frequency of digestive disorders in HD (e.g., constipation, diarrhea, and vomiting) and their impact on the quality of life of patients, routine assessment for these symptoms is recommended in order to ensure their management.

Their diagnostic workup should be conducted by the relevant specialists (general and digestive examination, biological and radiological tests, scan, fibroscopy, colonoscopy, etc.). Fecal impaction should be routinely investigated where there is constipation/ diarrhea ("false" diarrhea) and/or vomiting. Vomiting is sometimes intractable. If no specific etiology is identified, the following should be considered: staggering meals, reviewing the patients' posture during and after the meal, and possibly reducing antichoreic agents, in particular neuroleptics.

Excessive Perspiration

Excessive perspiration can occur at all stages of HD. It can be associated with other autonomic disorders and reflects discomfort or emotional burst when sudden.

In the case of excessive perspiration, care must be taken to ensure patients are well-hydrated, monitored and that their fluid and electrolyte balance is adjusted. Thyroid function and the possibility of infection should be assessed in case of excessive perspiration.

Weight Loss

Weight loss is often present in HD, sometimes prior to the appearance of other symptoms. It might occur despite normal, or even high calorie intake, due to a significant energy expenditure in HD patients. It can also be caused by swallowing disorders, depressive syndrome with reduced appetite or gastrointestinal disturbance and gut abnormalities due to enteric neuron dysfunction (118).

Good nutritional care is a fundamental element of the management of HD (Grade C) (119, 120). Early assessment by a dietitian or nutritionist, and regular timely reviews of nutritional needs are recommended. Factors such as swallowing ability, cognitive changes, behavior, mood, and general functional ability should be considered to determine possible other causes of weight loss (Grade C) (23, 120–123). A multidisciplinary approach is recommended and may include a Speech Language Therapist and an Occupational Therapist to assist with swallowing, positioning and feeding aids. Screening tools

for malnutrition [e.g., malnutrition Universal Screening Tool (MUST)] are recommended.

A high Body Mass Index (BMI) within normal values should be maintained if possible and medical and/or social intervention is recommended when unintended weight loss is higher than 10% within last 3–6 months or when BMI is $<20 \text{ kg/m}^2$ and unintentional weight loss of 5% is observed within last 3–6 months. When weight loss is observed, high-calorie and high-protein food supplements should be prescribed under instruction and monitored by a dietician/nutritionist (Grade C) (124, 125).

A Mediterranean diet may improve Quality of Life and nutritional composition (Grade C) (126).

In case of the initiation of antidepressant and/or neuroleptic treatments, treatments inducing weight gain should be preferred in patients with significant weight loss, whilst treatments inducing weight loss should be avoided (these effects can vary from one patient to another) (Grade C) (127).

Advanced care planning is essential and alternative feeding methods (PEG, see swallowing disorders) should be anticipated and discussed with relatives and patients still able to understand the benefits and risks of the intervention.

Hypersalivation

Hypersalivation can be troublesome in HD patients when associated with a salivary incontinence (caused by poor oral occlusion and or fault swallowing).

In the absence of a specific treatment for HD, drugs used in other chronic diseases may be considered to reduce salivary secretion: scopolamine given percutaneously, atropine given orally or other drugs that have an anticholinergic effect (amitriptyline), whilst watching out for iatrogenic risks, in particular confusional state, constipation, ocular hypertension and urinary retention. Injections of botulinum toxin into the salivary glands may be considered in a specialized setting if oral or oral mucosa treatment options have not induced benefit or were not well-tolerated.

Reduced Lung Function and Respiratory Muscle Strength

Reduced lung function and respiratory muscle strength are not only associated with end stage disease but occur much earlier, with evidence of some upper airway changes in pre-symptomatic individuals and reduction of cough effectiveness, reduced lung volume, and impaired respiratory strength by mid-disease. Along with changes in posture reduced exercise capacity, these impairments negatively impact respiratory function, leaving patients vulnerable to respiratory infections.

Home-based respiratory muscle training program appeared to improve pulmonary function in manifest HD patients but had only a small effect on swallowing function, dyspnea, and exercise capacity (Grade B) (128).

CONCLUSION

The EHDN guidelines task force provides here scientific and consensual guidelines from experts from 15 European experts from the national and steering committees and 73 worldwide

additional experts from 25 countries. Whereas, the literature extraction and scoring extent from 1965 to 2015, experts' input extended until October 2018. To ensure the validity of the guidelines in the light of the latest scientific results, two authors reviewed the literature from 2015 to 2019. They extracted 573 abstracts and selected the 17 relevant studies to HD management, which were then added to the grids. Two authors analyzed them separately and assigned each of them a level of scientific evidence. Because these recent relevant studies were not used to formulate recommendations reviewed by the International Multidisciplinary HD Health Professionals group, they are mentioned in the conclusion. Except for deutetrabenazine (Grade A) (129, 130), none of the studies justified to modify the recommendations. Deutetrabenazine may indeed be proposed as an alternative to tetrabenazine for the treatment of chorea in countries where the marketing authorization is already obtained, like in the USA. In addition, a number Grade B and C studies were in agreement with the current recommendations and reinforce the interest of rehabilitation (131–135). Therefore, as they stand, with this precision, these guidelines are likely to serve as international for care in HD. They are likely to support both general practitioners and specialists' decisions. Patients associations and patients themselves may use them and also disseminate them to inform their doctors.

It becomes increasingly clear that the cost of health is one of the major issues of public policy. In countries where there is a medical insurance system, the question of the choice of therapeutic care or medication and rehabilitation in the insured basket constitutes a central issue. The difficulty is even greater in rare diseases such as HD because the number of patients is too small to carry out double-blind placebo-controlled studies on large cohorts (Grade A) as required for the selection of health policies according to evidence-based medicine. In this work, based on therapeutic trials conducted between 1965 and 2015, only one grade A study was found among 376 studies analyzed, which is insufficient to eliminate or recommend enough products to meet the patients' needs. In parallel, thanks to specific international networks dedicated to HD (EHDN, HSG, and ERN) experts' know-how has increased with a knowledge-learning culture over time. In this context, the French Ministry of Health has labeled Rare Diseases Reference Centers in 2004, imposing on them various duties, one of which is producing National Protocols for Diagnostics and Care (NPDC). These protocols are designed as a combination of comprehensive literature reviews and expert consensus combining the work of an expert panel, and then its validation by outside experts to compensate for the information that is lacking. The recommendations from these NPDCs made it possible to provide decision-makers with comprehensive information based on an adapted version of evidence-based medicine to rare diseases. In addition, they allowed the health professional to refer to a document to answer their questions of day-to-day care. EHDN, with more than 2,000 members in 50 countries, is concerned by the relevance of prescriptions, medical procedures, hospital stays, care pathways, and care arrangements. It thus commissioned an international adaptation of the French NPDC. To give it an international value, we replaced face-to-face meetings with

electronic votes and added international committees and patient associations to national committees. Thus, beyond offering international guidelines to practitioners for the management of HD, this document proposes a method that is likely usable in all rare diseases.

AUTHOR CONTRIBUTIONS

A-CB-L supervised the elaboration of the guidelines. OA, KY, CS-G, and RM selected the studies to be analyzed. A-CB-L, KY, CP, CS-G, and DR analyzed each study and assigned a level of scientific evidence. Members of the National Committees (A-CB-L, CV, KY, CP, CS-G, OA, DR, and DC) formulated initial recommendations for each HD symptom. Members of the Steering Committee (A-CB-L, JF, KY, AR, MB, DC, RR, GD, DR, FS, KS, and J-MB) reviewed the initial recommendations and supervised the writing of the final recommendations. RM supervised the online surveys, analyzed the results, and assisted the Steering Committee in the writing of the recommendations. Members of the Steering Committee and RM wrote the manuscript (original draft preparation, review, and editing).

FUNDING

The work was supported by European Huntington's Disease Network, by the National Reference Center for Huntington's Disease (French Ministry of Health) and by NeurATRIS. This document was endorsed by and done in the framework of the European Reference Network for Rare Neurological Diseases (ERN-RDN). ERN-RDN was one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. Prof. Dr. Adrian Danek (ERN-RDN), Dr. José Esteban Muñoz García (ERN-RDN), and Dr. Jiri Kemplir (ERN-RDN) kindly reviewed the manuscript.

ACKNOWLEDGMENTS

We wish to thank Delphine Delbos for her help in conducting the online questionnaires, Gaëlle Désaméricq and Alasdair Ross for their participation in data extraction, Jessica Koehli for her help in contacting HD experts.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fneur.2019.00710/full#supplementary-material>

EUROPEAN HUNTINGTON'S DISEASE NETWORK GUIDELINES TASK FORCE

• Chair:

Prof. Anne-Catherine Bachoud-Lévi (MD, PhD), National Centre of reference for Huntington's disease, Henri Mondor Hospital, AP-HP, Creteil, France
email: bachoud@gmail.com

Phone: +336 80 72 84 17

• Steering Committee

- Prof. Jean-Marc Burgunder (MD), Swiss HD Center, NeuroZentrumSiloah and Department of Neurology, University of Bern, Bern, Switzerland
- Prof. Monica Busse (PhD), Centre for Trials Research, Cardiff University, United Kingdom
- David Craufurd (MB.BS, MSc, FRCPsych), Manchester Centre for Genomic Medicine, Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester; and Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
- Prof. Joaquim Ferreira (MD, PhD), Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal
- Prof. Giuseppe De Michele (MD), Department of Neurosciences, Federico II University, Naples, Italy
- Daniela Rae (MSc), Department of Clinical Genetics, NHS Grampian, Aberdeen, Scotland, United Kingdom
- Ralf Reilmann (MD, PhD), George-Huntington-Institute & Department of Radiology, Universitaetsklinikum Muenster, & Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tuebingen, Germany
- Prof. Anne Rosser (MA, PhD, MB.BChir, FRCP), IPMCN, School of Medicine, Cardiff University, United Kingdom
- Prof. Klaus Seppi (MD), Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
- Ferdinando Squitieri (MD), Huntington and Rare Diseases Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
- Katia Youssov (MD), National Centre of reference for Huntington's disease, Henri Mondor Hospital, AP-HP, Creteil, France

• French National Committee

- Prof. Anne-Catherine Bachoud-Lévi (MD, PhD), National Centre of reference for Huntington's disease, Henri Mondor Hospital, AP-HP, Creteil, France
- Prof. Christophe Verny (MD, PhD), Centre National de Référence des Maladies Neurodégénératives Service de Neurologie and UMR CNRS 6214 INSERM U1083, CHU d'Angers, Angers, France.
- Katia Youssov (MD), National Centre of reference for Huntington's disease, Henri Mondor Hospital, AP-HP, Creteil, France
- Charles Perrine (MD, PhD), National Center of reference for Huntington's disease, Genetic department, Sapètrière Hospital, Paris, France.
- Clarisse Scherer-Gagou (MD), Centre Hospitalier Universitaire d'Angers, Département de Neurologie, Angers, France
- Olivier Audrey (MSc), Département de Neurologie, Centre Hospitalier Universitaire d'Angers, Angers, France

- **United Kingdom National Committee**

- Daniela Rae (MSc), Department of Clinical Genetics, NHS Grampian, Aberdeen, Scotland, United Kingdom
- David Craufurd (MB.BS, MSc, FRCPsych), St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

- **Project Manager**

- Renaud Massart (PhD), National Centre of reference for Huntington's disease, Henri Mondor Hospital, AP-HP, Creteil, France

CONTRIBUTORS

- **Patients' associations**

- Astri Arnesen, European Huntington Association
- Dina De Sousa, European Huntington Association
- Emilie Hermant, DingDingDong, France
- Barbara D'Alessio, LIRH Foundation, Italy and European Huntington Association
- Xi Cao, Chinese Huntington's Disease Association

- **International Multidisciplinary Group of Huntington's Disease Health Professionals**

- **Dentist**

- Åsa Mårtensson, Folk tandvården Västra Götaland, Odontology, Göteborg, Sweden

- **Geneticists**

- Marina Frontali, CNR Institute of Translational Pharmacology, Rome, Italy
- Paula Helderman, Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands
- Carmen Ayuso, Biomedical Research Institute Fundación Jimenez Díaz, University Hospital Fundación Jiménez Díaz, Madrid, Spain
- Christine de Die-Smulders, Department Clinical Genetics, Maastricht UMC+, The Netherlands

- **Neurologists**

- Anette Torvin Møller, Aarhus University Hospital, Denmark
- Cyril Goizet, Centre de Référence Neurogénétique, Service de Génétique Médicale, CHU de Bordeaux, France
- Raymund A.C. Roos, Medical Center, Leiden University, The Netherlands
- Wim Vandenberghe, Department of Neurology, University Hospitals of Leuven, Belgium
- Clémence Simonin, Centre Hospitalier Universitaire de Lille, Département de Neurologie et des Mouvements Anormaux, Lille, France

- Peter K. Panegyres, Neurodegenerative Disorders Research Pty Ltd, West Perth, Australia
- Christian Neumann, Neurology Department, Forth Valley Royal Hospital, Larbert, United Kingdom
- Jennifer Goldman, Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University, Chicago, IL USA
- Laura Buyan Dent, University of Wisconsin Hospital and Clinics, Madison, WI USA
- Madaline Harrison, Department of Neurology, University of Virginia, Charlottesville, VA USA
- Pedro J. Garcia Ruiz, Movement Disorder Unit, Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
- Susan L. Perlman, Department of Neurology, Ronald Reagan UCLA Medical Center, Los Angeles, CA USA
- Cesa Lorella Maria Scaglione, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- Carol Manning, Memory Disorders Clinic, Department of Neurology, University of Virginia, Charlottesville, VA USA
- Elizabeth Coulthard, Cognitive Neurology and Dementia Clinic, North Bristol NHS Trust, UNITED KINGDOM
- Sandra K. Kostyk, HDSA Center of Excellence of the Ohio State University Wexner Medical Center, Columbus, OH USA
- Yury Seliverstov, Neurogenetics Department of the Russian Academy of Medical Sciences in Moscow, Russia
- Lene Wermuth, Demenskliviken OUH, Odense Universitetshospital, Odense, Denmark
- Vasile Tibre, University of Medicine and Pharmacy of Cluj-Napoca, Romania
- Mayke Oosterloo, Department of Neurology, Maastricht UMC+, The Netherlands
- Carlos Juri, Department of Neurology, Pontificia Universidad Catolica de Chile, Santiago, Chile
- Annie Killoran, Department of Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA USA
- Mariana Spitz, Movement Disorders Unit, Neurology Department, University of São Paulo Medical School, São Paulo, Brazil
- Christine Tranchant, CHU de Strasbourg—Hôpital de Haute-pierre, Service de Neurologie, 67098, Strasbourg, France
- Fabienne Calvas, Inserm CIC 1436, CHU Toulouse, Université Toulouse III Paul Sabatier, Toulouse, France
- Maria Carolina Lobo de Almeida Garrett, Neurology Department of Faculty of Medicine University of Porto/Hospital São João, Porto, Portugal
- Eleni Zamba-Papanicolaou, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
- Yiolanda Christou, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
- Marina De Tommaso, School of Medicine: Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy
- João Massano, Department of Neurology & Movement Disorders and Functional Surgery Unit, Centro Hospitalar de São João, Porto, Portugal

- Katrin Gross-Paju, Center for Neurological Diseases, West-Tallinn Central Hospital, Tallinn University of Technology, Estonia
- Silvia Romano, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso NESMOS, Sapienza University, Rome, Italy
- Caterina Mariotti, Fondazione IRCCS Istituto Neurologico "C. Besta", Milano, Italy
- Jan Roth, Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
- Giovanni Ristori, Dipartimento di Neuroscienze Salute Mentale e Organi di Senso NESMOS, Sapienza University, Rome, Italy
- Clement Loy, Huntington Disease Service, Westmead Hospital, Sydney, Australia
- Javier Abril Jaramillo, Centro de Neurología Avanzada, Universidad de Sevilla, Spain
- Miriam Elena Velez Rojas, Instituto Nacional de Ciencias Neurológicas, Lima, Peru
- Maria Judit Molnar, Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary
- Manho Kim, Department of Neurology, Seoul National University Hospital, South Korea

● Neuropsychologists

- Johanna Maria Helena Nijsten, Archipel Knowledge Centre for Specialized Care, Archipelcare group, Eindhoven, The Netherlands
- Quirine Ingeborg Slik, Topaz Overduin, Katwijk, The Netherlands
- David J. Moser, Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA USA
- Saul Martinez Horta, Unidad de Trastornos del Movimiento, Servicio de Neurología Hospital de la Santa Creu i Sant Pau, Instituto de Investigación Biomédica Sant Pau, Spain
- Filipa Lima Ramos Santos Júlio, Huntington's Portuguese Association, Lisboa, Portugal

● Nurses

- Paul van Roosmalen, Archipel group, Eindhoven, The Netherlands
- Katja Jasmin Christener, Department Huntington, Acute care clinic, care and rehabilitation, Siloah, Gümligen, Switzerland
- Graça Morgado, Pôle Recherche clinique Santé Publique, Hôpital H. Mondor - A. Chenevier, AP-HP, Créteil, France
- Joanne Dysart, Huntington's Disease Service, Auckland City Hospital, Auckland, New-Zealand

● Physiotherapists

- Elzbieta Mirek, Department of Rehabilitation in Neurology and Psychiatry, University School of Education, Kraków, Poland; Department of Neurology and Neurorehabilitation, John Paul's II Hospital, Kraków, Poland
- Deborah Kegelmeyer, Physical Therapy Division, SAMP, Ohio State University, Columbus, OH USA
- Anne Kloos, Health and Rehabilitation Sciences, Ohio State University, Columbus, OH USA
- Magdalena Filip, Department of Rehabilitation in Neurology and Psychiatry, University School of Education, Kraków, Poland; Department of Neurology and Neurorehabilitation, John Paul's II Hospital, Kraków, Poland
- Karin Bunnig, Topaz Overduin, Katwijk, The Netherlands

● Psychiatrists

- Andreia Norton, Department of Psychiatry, Hospital Magalhães Lemos, Porto, Portugal
- Elvina May-Yin Chu, The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
- Peggy Nopoulos, Department of Psychiatry, University of Iowa Carver College of Medicine, Iowa City, IA USA
- Mark Walterfang, Neuropsychiatry Unit, Royal Melbourne Hospital, Melbourne, Australia
- Oleg R. Smirnov, Moscow Research Institute of Psychiatry, Moscow, Russia
- Michele Raja, Private practice, Rome, Italy
- Erik van Duijn, Leiden University Medical Center, Leiden, The Netherlands
- Hugh Rickards, Department of Neurology, University of Birmingham, Birmingham, United Kingdom

● Psychologists

- Gioia A. Jacopini, Associazione Italiana Corea di Huntington, Rome, Italy
- Nina Hofstetter, Huntington's Center South, Kbo-Isar-Amper Hospital, Taufkirchen, Germany
- Rafaela Alexandra Policarpo da Rosa, The CNS - Campus Neurológico Sénior, Lisbon, Portugal
- Ariane Van Tongerloo, Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
- Asuncion Martinez Descals, International Huntington Association, Biomedical Research Institute Fundación Jimenez Diaz, Clinical Genetics Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
- Sarah Mason, Department of Clinical Neurosciences, Cambridge Center for Brain Repair, University of Cambridge, Cambridge, United Kingdom.

REFERENCES

1. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. *Cochrane Database Syst Rev.* (2009) 8:CD006456. doi: 10.1002/14651858.CD006456.pub2
2. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. *Lancet Neurol.* (2011) 10:83–98. doi: 10.1016/S1474-4422(10)70245-3
3. Venuto CS, McGarry A, Ma Q, Kiebertz K. Pharmacologic approaches to the treatment of Huntington's disease. *Mov Disord.* (2012) 27:31–41. doi: 10.1002/mds.23953

4. Armstrong MJ, Miyasaki JM, American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. *Neurology*. (2012) 79:597–603. doi: 10.1212/WNL.0b013e318263c443
5. Killoran A, Biglan KM. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? *Mov Disord*. (2014) 29:1404–13. doi: 10.1002/mds.26014
6. Priller J, Ecker D, Landwehrmeyer B, Craufurd D. A Europe-wide assessment of current medication choices in Huntington's disease. *Mov Disord*. (2008) 23:1788. doi: 10.1002/mds.22188
7. Burgunder J-M, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. *PLoS Curr*. (2011) 3:RRN1260. doi: 10.1371/currents.RRN1260
8. Paulsen JS, Miller AC, Hayes T, Shaw E. Cognitive and behavioral changes in Huntington disease before diagnosis. *Handb Clin Neurol*. (2017) 144:69–91. doi: 10.1016/B978-0-12-801893-4.00006-7
9. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. *Neurology*. (2006) 66:366–72. doi: 10.1212/01.wnl.0000198586.85250.13
10. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. *Curr Med Res Opin*. (1984) 9:329–38. doi: 10.1185/03007998409109601
11. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. *J Neurol Neurosurg Psychiatry*. (1984) 47:844–7. doi: 10.1136/jnnp.47.8.844
12. van de Zande NA, Massey TH, McLauchlan D, Pryce Roberts A, Zutt R, Wardle M, et al. Clinical characterization of dystonia in adult patients with Huntington's disease. *Eur J Neurol*. (2017) 24:1140–7. doi: 10.1111/ene.13349
13. Barbeau A. L-dopa and juvenile Huntington's disease. *Lancet*. (1969) 2:1066. doi: 10.1016/S0140-6736(69)90662-X
14. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. *Med J Aust*. (1974) 1:393–4.
15. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. *J Neurol Neurosurg Psychiatry*. (2000) 68:238–41. doi: 10.1136/jnnp.68.2.238
16. Vargas AP, Carod-Artal FJ, Bomfim D, Vázquez-Cabrera C, Dantas-Barbosa C. Unusual early-onset Huntingtons disease. *J Child Neurol*. (2003) 18:429–32. doi: 10.1177/08830738030180061301
17. Jongen PJ, Renier WO, Gabreëls FJ. Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic-rigid form. *Clin Neurol Neurosurg*. (1980) 82:251–61. doi: 10.1016/0303-8467(80)90017-7
18. Wang S-C, Lee-Chen G-J, Wang C-K, Chen C-M, Tang L-M, Wu Y-R. Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease. *Mov Disord*. (2004) 19:854–6. doi: 10.1002/mds.20093
19. Quinn L, Busse M. Physiotherapy clinical guidelines for Huntington's disease. *Neurodegener Dis Manage*. (2012) 2:21–31. doi: 10.2217/nmt.11.86
20. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. *BMC Neurol*. (2009) 9:62. doi: 10.1186/1471-2377-9-62
21. Huang CY, McLeod JG, Holland RT, Elliot C. Tetrabenazine in the treatment of Huntington's chorea. *Med J Aust*. (1976) 1:583–4.
22. Monaco AD, Nuzzi A, Parente A, Lavermicocca V, Chiarelli T, Tommaso MD, et al. I03 swallowing function in the early, middle and late stages of Huntington's disease. *J Neurol Neurosurg Psychiatry*. (2014) 85(Suppl. 1):A58. doi: 10.1136/jnnp-2014-309032.165
23. Kagel MC, Leopold NA. Dysphagia in Huntington's disease: a 16-year retrospective. *Dysphagia*. (1992) 7:106–14. doi: 10.1007/BF02493441
24. Giddens C, Coleman EA, Adams C. Home program of speech therapy in Huntington's disease. *J Med Speech Lang Pathol*. (2010) 18:1–9.
25. Carella F, Scaioli V, Ciano C, Binelli S, Oliva D, Girotti F. Adult onset myoclonic Huntington's disease. *Mov Disord*. (1993) 8:201–5. doi: 10.1002/mds.870080216
26. Novom S, Danna S, Goldberg MA. Intention myoclonus in Huntington's disease. *Bull Los Angeles Neurol Soc*. (1976) 41:82–4.
27. Previdi P, Borgonovi R. Myoclonus and Huntington's chorea: description of a case. *Ital J Neurol Sci*. (1980) 1:189–91. doi: 10.1007/BF02335850
28. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's disease patients: a case series. *BMC Neurol*. (2006) 6:11. doi: 10.1186/1471-2377-6-11
29. Thompson PD, Bhatia KP, Brown P, Davis MB, Pires M, Quinn NP, et al. Cortical myoclonus in Huntington's disease. *Mov Disord*. (1994) 9:633–41. doi: 10.1002/mds.870090609
30. Vogel CM, Drury I, Terry LC, Young AB. Myoclonus in adult Huntington's disease. *Ann Neurol*. (1991) 29:213–5. doi: 10.1002/ana.410290217
31. Landau ME, Cannard KR. EEG characteristics in juvenile Huntington's disease: a case report and review of the literature. *Epileptic Disord*. (2003) 5:145–8.
32. Keresi S, Schlagenhauff RE, Richardson KS. Myoclonic and major seizures in early adult Huntington's chorea: case-report and electro-clinical findings. *Clin Electroencephalogr*. (1980) 11:44–7. doi: 10.1177/155005948001100202
33. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. *Mov Disord*. (2008) 23:1100–7. doi: 10.1002/mds.21987
34. Delval A, Krystkowiak P, Blatt J-L, Dellioux M, Destée A, Derambure P, et al. Evolution of locomotion disorders in Huntington's disease. *Neurophysiol Clin*. (2008) 38:117–25. doi: 10.1016/j.neucli.2008.01.003
35. Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A, et al. Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study. *Clin Rehabil*. (2007) 21:603–13. doi: 10.1177/0269215507075495
36. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington's disease: a prospective intervention study. *PLoS Curr*. (2013) 5:ecurrents.hd.9504af71e0d1f87830c25c394be47027. doi: 10.1371/currents.hd.9504af71e0d1f87830c25c394be47027
37. Piira A, van Walsem MR, Mikalsen G, Oie L, Frich JC, Knutsen S. Effects of a two-year intensive multidisciplinary rehabilitation program for patients with Huntington's disease: a prospective intervention study. *PLoS Curr*. (2014) 6:ecurrents.hd.2c56ceef7f9f8e239a59ecf2d94cddac. doi: 10.1371/currents.hd.2c56ceef7f9f8e239a59ecf2d94cddac
38. Kegelmeyer D, Fritz N, Kostyk S, Kloos A. J04 The effect of video game-based exercise on dynamic balance and mobility in individuals with Huntington's disease. *J Neurol Neurosurg Psychiatry*. (2010) 81(Suppl. 1):A40. doi: 10.1136/jnnp.2010.222661.4
39. Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R, et al. A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease. *J Neurol Phys Ther*. (2013) 37:149–58. doi: 10.1097/NPT.0000000000000016
40. Quinn L, Debono K, Dawes H, Rosser AE, Nemeth AH, Rickards H, et al. Task-specific training in Huntington disease: a randomized controlled feasibility trial. *Phys Ther*. (2014) 94:1555–68. doi: 10.2522/ptj.20140123
41. Ciancarelli I, Tozzi Ciancarelli MG, Carolei A. Effectiveness of intensive neurorehabilitation in patients with Huntington's disease. *Eur J Phys Rehabil Med*. (2013) 49:189–95.
42. Khalil H, Quinn L, van Deursen R, Dawes H, Playle R, Rosser A, et al. What effect does a structured home-based exercise programme have on people with Huntington's disease? A randomized, controlled pilot study. *Clin Rehabil*. (2013) 27:646–58. doi: 10.1177/0269215512473762
43. Thaut MH, Miltner R, Lange HW, Hurt CP, Hoemberg V. Velocity modulation and rhythmic synchronization of gait in Huntington's disease. *Mov Disord*. (1999) 14:808–19. doi: 10.1002/1531-8257(199909)14:5<808::AID-MDS1014>3.0.CO;2-J
44. Bohlen S, Ekwall C, Hellström K, Vesterlin H, Björnefur M, Wiklund L, et al. Physical therapy in Huntington's disease-toward objective assessments? *Eur J Neurol*. (2013) 20:389–93. doi: 10.1111/j.1468-1331.2012.03760.x
45. Mirek E, Filip M, Banaszkiwicz K, Rudzinska M, Szymura J, Pasiut S, et al. The effects of physiotherapy with PNF concept on gait and balance of patients with Huntington's disease - pilot study. *Neurol Neurochir Pol*. (2015) 49:354–7. doi: 10.1016/j.pjnns.2015.09.002

46. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. *Clin Neuropharmacol.* (2002) 25:263–5. doi: 10.1097/00002826-200209000-00007
47. Bonelli RM, Niederwieser G, Tribl GG, Költringer P. High-dose olanzapine in Huntington's disease. *Int Clin Psychopharmacol.* (2002) 17:91–3. doi: 10.1097/00004850-200203000-00009
48. Ciammola A, Sassone J, Colciago C, Mencacci NE, Poletti B, Ciarmiello A, et al. Aripiprazole in the treatment of Huntington's disease: a case series. *Neuropsychiatr Dis Treat.* (2009) 5:1–4. doi: 10.2147/NDT.S4165
49. Knowing MR, Wrench W. Treatment of Huntington's chorea with sulpiride. *S Afr Med J.* (1991) 79:169.
50. Kloos AD, Kegelmeyer DA, White SE, Kostyk SK. The impact of different types of assistive devices on gait measures and safety in Huntington's disease. *PLoS ONE.* (2012) 7:e30903. doi: 10.1371/journal.pone.0030903
51. Nash MC, Ferrell RB, Lombardo MA, Williams RB. Treatment of bruxism in Huntington's disease with botulinum toxin. *J Neuropsychiatry Clin Neurosci.* (2004) 16:381–2. doi: 10.1176/jnp.16.3.381-a
52. Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease. *Mov Disord.* (2000) 15:171–3. doi: 10.1002/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y
53. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. *Lancet.* (1974) 1:104–7. doi: 10.1016/S0140-6736(74)92338-1
54. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. *Mov Disord.* (2008) 23:721–6. doi: 10.1002/mds.21920
55. Cruickshank TM, Thompson JA, Domínguez DJF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, et al. The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study. *Brain Behav.* (2015) 5:e00312. doi: 10.1002/brb3.312
56. Metzler-Baddeley C, Cantera J, Coulthard E, Rosser A, Jones DK, Baddeley RJ. Improved executive function and callosal white matter microstructure after rhythm exercise in Huntington's disease. *J Huntingtons Dis.* (2014) 3:273–83. doi: 10.3233/JHD-140113
57. Papoutsis M, Labuschagne I, Tabrizi SJ, Stout JC. The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation. *Mov Disord.* (2014) 29:673–83. doi: 10.1002/mds.25864
58. Ludlow CL, Connor NP, Bassich CJ. Speech timing in Parkinson's and Huntington's disease. *Brain Lang.* (1987) 32:195–214. doi: 10.1016/0093-934X(87)90124-6
59. Saldert C, Fors A, Ströberg S, Hartelius L. Comprehension of complex discourse in different stages of Huntington's disease. *Int J Lang Commun Disord.* (2010) 45:656–69. doi: 10.3109/13682820903494742
60. Ferm U, Sahlin A, Sundin L, Hartelius L. Using talking mats to support communication in persons with Huntington's disease. *Int J Lang Commun Disord.* (2010) 45:523–36. doi: 10.3109/13682820903222809
61. Bora E, Velakoulis D, Walterfang M. Social cognition in Huntington's disease: a meta-analysis. *Behav Brain Res.* (2016) 297:131–40. doi: 10.1016/j.bbr.2015.10.001
62. Aretouli E, Brandt J. Episodic memory in dementia: characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases. *Arch Clin Neuropsychol.* (2010) 25:396–409. doi: 10.1093/arclin/acq038
63. Beste C, Saft C, Andrich J, Müller T, Gold R, Falkenstein M. Time processing in Huntington's disease: a group-control study. *PLoS ONE.* (2007) 2:e1263. doi: 10.1371/journal.pone.0001263
64. Rao AK, Marder KS, Uddin J, Rakitin BC. Variability in interval production is due to timing-dependent deficits in Huntington's disease. *Mov Disord.* (2014) 29:1516–22. doi: 10.1002/mds.25998
65. Cope TE, Grube M, Singh B, Burn DJ, Griffiths TD. The basal ganglia in perceptual timing: timing performance in Multiple System Atrophy and Huntington's disease. *Neuropsychologia.* (2014) 52:73–81. doi: 10.1016/j.neuropsychologia.2013.09.039
66. Lawrence AD, Watkins LH, Sahakian BJ, Hodges JR, Robbins TW. Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. *Brain.* (2000) 123(Pt 7):1349–64. doi: 10.1093/brain/123.7.1349
67. Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, et al. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease. *Parkinsonism Relat Disord.* (2016) 25:58–64. doi: 10.1016/j.parkreldis.2016.02.008
68. van Duijn E, Craufurd D, Hubers AAM, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). *J Neurol Neurosurg Psychiatry.* (2014) 85:1411–8. doi: 10.1136/jnnp-2013-307343
69. Epping EA, Mills JA, Beglinger LJ, Fiedorowicz JG, Craufurd D, Smith MM, et al. Characterization of depression in prodromal Huntington disease in the neurobiological predictors of HD (PREDICT-HD) study. *J Psychiatr Res.* (2013) 47:1423–31. doi: 10.1016/j.jpsychires.2013.05.026
70. Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, et al. Results of the citalopram to enhance cognition in Huntington disease trial. *Mov Disord.* (2014) 29:401–5. doi: 10.1002/mds.25750
71. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington's disease. *J Neuropsychiatry Clin Neurosci.* (1996) 8:209–10. doi: 10.1176/jnp.8.2.209
72. Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington's disease. *J Neuropsychiatry Clin Neurosci.* (1994) 6:154–9. doi: 10.1176/jnp.6.2.154
73. Evans DL, Pedersen CA, Tancer ME. ECT in the treatment of organic psychosis in Huntington's disease. *Convuls Ther.* (1987) 3:145–50.
74. Wesson M, Boileau NR, Perlmutter JS, Paulsen JS, Barton SK, McCormack MK, et al. Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease. *J Huntingtons Dis.* (2018) 7:239–49. doi: 10.3233/JHD-180299
75. Fiedorowicz JG, Mills JA, Ruggie A, Langbehn D, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. Suicidal behavior in prodromal Huntington disease. *Neurodegener Dis.* (2011) 8:483–90. doi: 10.1159/000327754
76. van Duijn E, Kingma EM, van der Mast RC. Psychopathology in verified Huntington's disease gene carriers. *J Neuropsychiatry Clin Neurosci.* (2007) 19:441–8. doi: 10.1176/jnp.2007.19.4.441
77. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. *J Neuropsychiatry Clin Neurosci.* (1996) 8:338–40. doi: 10.1176/jnp.8.3.338
78. De Marchi N, Daniele F, Ragone MA. Fluoxetine in the treatment of Huntington's disease. *Psychopharmacology (Berl).* (2001) 153:264–6. doi: 10.1007/s002130000575
79. Désaméric G, Dolbeau G, Verny C, Charles P, Durr A, Youssov K, et al. Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort. *PLoS ONE.* (2014) 9:e85430. doi: 10.1371/journal.pone.0085430
80. Colosimo C, Cassetta E, Bentivoglio AR, Albanese A. Clozapine in Huntington's disease. *Neurology.* (1995) 45:1023–4. doi: 10.1212/WNL.45.5.1023
81. Johnston TG. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms. *Int Clin Psychopharmacol.* (2011) 26:114–9. doi: 10.1097/YIC.0b013e3283407775
82. Grove VE, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. *N Engl J Med.* (2000) 343:973–4. doi: 10.1056/NEJM200009283431316
83. Shen Y-C. Lamotrigine in motor and mood symptoms of Huntington's disease. *World J Biol Psychiatry.* (2008) 9:147–9. doi: 10.1080/15622970701332520
84. Levy R, Czernecki V. Apathy and the basal ganglia. *J Neurol.* (2006) 253(Suppl. 7):VII54–61. doi: 10.1007/s00415-006-7012-5
85. Bouwens JA, van Duijn E, van der Mast RC, Roos RAC, Giltay EJ. Irritability in a prospective cohort of Huntington's disease mutation carriers. *J Neuropsychiatry Clin Neurosci.* (2015) 27:206–12. doi: 10.1176/appi.neuropsych.14030051
86. Squitieri F, Cannella M, Porcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. *Neuropsychiatry Neuropsychol Behav Neurol.* (2001) 14:69–72.
87. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive

- symptoms in Huntington's disease. *Ann Clin Psychiatry*. (2008) 20:1–3. doi: 10.1080/10401230701844802
88. Read J, Jones R, Owen G, Leavitt BR, Coleman A, Roos RAC, et al. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. *J Huntingtons Dis*. (2013) 2:159–75. doi: 10.3233/JHD-130051
 89. Patzold T, Brüne M. Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline. *Neuropsychiatry Neuropsychol Behav Neurol*. (2002) 15:216–9.
 90. Jhanjee A, Anand KS, Bajaj BK. Hypersexual features in Huntington's disease. *Singapore Med J*. (2011) 52:e131–3.
 91. Tavares A, Volpe FM. Cyproterone for treatment of hypersexuality in an elderly Huntington's disease patient. *Prog Neuropsychopharmacol Biol Psychiatry*. (2008) 32:1994–5. doi: 10.1016/j.pnpbp.2008.07.010
 92. Rich SS, Ovsiew F. Leuprolide acetate for exhibitionism in Huntington's disease. *Mov Disord*. (1994) 9:353–7. doi: 10.1002/mds.870090317
 93. Blass DM, Steinberg M, Leroi I, Lyketos CG. Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. *Am J Psychiatry*. (2001) 158:1966–72. doi: 10.1176/appi.ajp.158.12.1966
 94. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. *Acta Neurol Scand*. (2002) 105:441–4. doi: 10.1034/j.1600-0404.2002.01197.x
 95. Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantine in the treatment of Huntington's disease. *J Natl Med Assoc*. (2006) 98:1353–5.
 96. Madhusoodanan S, Brenner R, Moise D, Sindagi J, Brafman I. Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. *Ann Clin Psychiatry*. (1998) 10:117–20. doi: 10.3109/10401239809148945
 97. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. *Am J Geriatr Psychiatry*. (1998) 6:347–9. doi: 10.1097/00019442-1998060640-00013
 98. Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. *J Neuropsychiatry Clin Neurosci*. (2010) 22:352c e4–352 e5. doi: 10.1176/jnp.2010.22.3.352.e4
 99. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. *J Clin Psychopharmacol*. (1997) 17:134–5. doi: 10.1097/00004714-199704000-00023
 100. Vallette N, Gosselin O, Kahn JP. Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case. *Encephale*. (2001) 27:169–71.
 101. Yavuz KF, Ulusoy S, Alniak I. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease. *J Neuropsychiatry Clin Neurosci*. (2013) 25:E31. doi: 10.1176/appi.neuropsych.12040097
 102. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. *Psychosomatics*. (2006) 47:70–2. doi: 10.1176/appi.psy.47.1.70
 103. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to huntington's disease: a case report. *Can J Psychiatry*. (2004) 49:413. doi: 10.1177/070674370404900617
 104. Edlinger M, Seppi K, Fleischhacker W, Hofer A. Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. *Int Clin Psychopharmacol*. (2013) 28:214–6. doi: 10.1097/YIC.0b013e328361e145
 105. Sajatovic M, Verbanac P, Ramirez LF, Meltzer HY. Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. *Neurology*. (1991) 41:156. doi: 10.1212/WNL.41.1.156
 106. Lin W-C, Chou Y-H. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. *Am J Psychiatry*. (2008) 165:1207–8. doi: 10.1176/appi.ajp.2008.08040503
 107. Nakano T, Ono S, Yamaguchi J, Sugimoto R, Yamaguchi N, Morimoto Y, et al. Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington's disease. *J Neurol*. (2013) 260:312–4. doi: 10.1007/s00415-012-6720-2
 108. Rej S, Desautels R. Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease. *J Neuropsychiatry Clin Neurosci*. (2013) 25:E33–4. doi: 10.1176/appi.neuropsych.12070164
 109. Korenyi C, Whittier JR. Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin). *Psychiatr Q*. (1967) 41:203–10. doi: 10.1007/BF01573339
 110. Bellosta Diago E, Pérez Pérez J, Santos Lasaosa S, Vilorio Alebesque A, Martínez Horta S, Kulisevsky J, et al. Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. *Parkinsonism Relat Disord*. (2017) 44:95–100. doi: 10.1016/j.parkreldis.2017.09.013
 111. Arnulf I, Nielsen J, Lohmann E, Schieffer J, Schieffer J, Wild E, et al. Rapid eye movement sleep disturbances in Huntington disease. *Arch Neurol*. (2008) 65:482–8. doi: 10.1001/archneur.65.4.482
 112. Cochen V, Degos JD, Bachoud-Lévi AC. Efficiency of carbamazepine in the treatment of micturitional disturbances in Huntington disease. *Neurology*. (2000) 55:1934. doi: 10.1212/WNL.55.12.1934
 113. Lewis D, Fiske J, Dougall A. Access to special care dentistry, part 7. Special care dentistry services: seamless care for people in their middle years—part 1. *Br Dent J*. (2008) 205:305–17. doi: 10.1038/sj.bdj.2008.803
 114. Manley G, Lane H, Carlsson A, Ahlberg B, Mårtensson Å, Nilsson MB, et al. Guideline for oral healthcare of adults with Huntington's disease. *Neurodegener Dis Manag*. (2012) 2:55–65. doi: 10.2217/nmt.11.68
 115. Boyle CA, Frölander C, Manley G. Providing dental care for patients with Huntington's disease. *Dent Update*. (2008) 35:333–6. doi: 10.12968/denu.2008.35.5.333
 116. Moline DO, Iglehart DR. Huntington's chorea: review and case report. *Gen Dent*. (1985) 33:131–3.
 117. Cangemi CF, Miller RJ. Huntington's disease: review and anesthetic case management. *Anesth Prog*. (1998) 45:150–3.
 118. Sciacca S, Favellato M, Madonna M, Metro D, Marano M, Squitieri F. Early enteric neuron dysfunction in mouse and human Huntington disease. *Parkinsonism Relat Disord*. (2017) 34:73–4. doi: 10.1016/j.parkreldis.2016.10.017
 119. Brotherton A, Campos L, Rowell A, Zoia V, Simpson SA, Rae D. Nutritional management of individuals with Huntington's disease: nutritional guidelines. *Neurodegener Dis Manage*. (2012) 2:33–43. doi: 10.2217/nmt.11.69
 120. Trejo A, Tarrats RM, Alonso ME, Boll M-C, Ochoa A, Velásquez L. Assessment of the nutrition status of patients with Huntington's disease. *Nutrition*. (2004) 20:192–6. doi: 10.1016/j.nut.2003.10.007
 121. Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wu J, et al. Effect of donepezil on motor and cognitive function in Huntington disease. *Neurology*. (2006) 67:1268–71. doi: 10.1212/01.wnl.0000238106.10423.00
 122. Leopold NA, Kagel MC. Dysphagia in Huntington's disease. *Arch Neurol*. (1985) 42:57–60. doi: 10.1001/archneur.1985.04060010063017
 123. Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. *Mov Disord*. (1996) 11:542–8. doi: 10.1002/mds.870110509
 124. Trejo A, Boll M-C, Alonso ME, Ochoa A, Velásquez L. Use of oral nutritional supplements in patients with Huntington's disease. *Nutrition*. (2005) 21:889–94. doi: 10.1016/j.nut.2004.12.012
 125. Popovic V, Svetel M, Djurovic M, Petrovic S, Doknic M, Pekic S, et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. *Eur J Endocrinol*. (2004) 151:451–5. doi: 10.1530/eje.0.1510451
 126. Rivadeneyra J, Cubo E, Polo CG, Mariscal N, Calvo S, Mateos A, et al. J14 mediterranean diet and nutritional composition of patients with Huntington's disease. Spanish multicenter study of the European group for Huntington's disease. *J Neurol Neurosurg Psychiatry*. (2014) 85(Suppl. 1):A69–70. doi: 10.1136/jnnp-2014-309032.197
 127. Cubo E, Rivadeneyra J, Mariscal N, Armesto D, Mateos A, Camara R. The relationship between dietary intake, nutrition status and Huntington's disease severity (P1.050). *Neurology*. (2014) 4:78–85.
 128. Reyes A, Cruickshank T, Nosaka K, Ziman M. Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: a pilot randomised controlled trial. *Clin Rehabil*. (2015) 29:961–73. doi: 10.1177/0269215514564087

129. Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. *Drug Des Devel Ther.* (2018) 12:313–9. doi: 10.2147/DDDT.S138828
130. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. *JAMA.* (2016) 316:40–50. doi: 10.1001/jama.2016.8011
131. Busse M, Quinn L, Drew C, Kelson M, Trubey R, McEwan K, et al. Physical activity self-management and coaching compared to social interaction in Huntington disease: results from the ENGAGE-HD randomized, controlled pilot feasibility trial. *Phys Ther.* (2017) 97:625–39. doi: 10.1093/ptj/pzx031
132. Frese S, Petersen JA, Ligon-Auer M, Mueller SM, Mihaylova V, Gehrig SM, et al. Exercise effects in Huntington disease. *J Neurol.* (2017) 264:32–9. doi: 10.1007/s00415-016-8310-1
133. Mueller SM, Gehrig SM, Petersen JA, Frese S, Mihaylova V, Ligon-Auer M, et al. Effects of endurance training on skeletal muscle mitochondrial function in Huntington disease patients. *Orphanet J Rare Dis.* 19 (2017) 12:184. doi: 10.1186/s13023-017-0740-z
134. Wallace M, Downing N, Lourens S, Mills J, Kim J-I, Long J, et al. Is there an association of physical activity with brain volume, behavior, and day-to-day functioning? A cross sectional design in prodromal and early huntington disease. *PLoS Curr.* (2016) 8:ecurrents.hd.cba6ea74972cf8412a73ce52eb018c1e. doi: 10.1371/currents.hd.cba6ea74972cf8412a73ce52eb018c1e
135. Fritz NE, Busse M, Jones K, Khalil H, Quinn L, Members of the Physiotherapy Working Group of the European Huntington's Disease Network. A classification system to guide physical therapy management in huntington disease: a case series. *J Neurol Phys Ther.* (2017) 41:156–63. doi: 10.1097/NPT.0000000000000188

Conflict of Interest Statement: J-MB was chair of the European Huntington's Disease Network (EHDN) during the completion of the work, and received honoraria for the duties involved in this position. AR received reimbursements as Co-Chair and Chair of the EHDN. RR is the owner of the George-Huntington-Institut GmbH and the QuantisMedis GmbH. He is a member of the EHDN Executive Committee and of the Huntington Study Group Executive Committee.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Bachoud-Lévi, Ferreira, Massart, Youssouf, Rosser, Busse, Craufurd, Reilmann, De Michele, Rae, Squitieri, Seppi, Perrine, Scherer-Gagou, Audrey, VERNY and Burgunder. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.



https://ec.europa.eu/health/ern_e



European Reference Network
for rare or low prevalence complex diseases

Network
Neurological Diseases
(ERN-RND)

Coordinator
Universitätsklinikum
Tübingen — Deutschland

www.ern-rnd.eu

Co-funded by the European Union

